RABIES VACCINE MARKET ANALYSIS

Market News

Key Developments-

• In 2016, Serum Institute of India, developed new rabies vaccine, RABIVAS-S, for countries with highest burden of rabies.
• The World Organization for Animal Health (OIE), a vaccine bank, was established in 2012 with production order for rabies vaccine of 50,000 doses in 31^st December 2016. The OIE recorded 16 million doses of vaccines in 24 countries for pre- and post-exposure prophylaxis treatment for rabies.
• In 2019, Yisheng Biopharma (Singapore) Pte Ltd stated that development of adjuvant rabies vaccine, PIKA which is composed of RABIPUR and polyisonic-polycytidcyclic acid, has completed its phase 2 clinical trial.
• In 2019, GlaxoSmithKline divested its rabies and tick-borne vaccine to Bavarian Nordic, and incurred payment of $36 million from Bavarian Nordic.
• In 2019, Asian subsidiary of GlaxoSmithKline divested its Chiron Behring Vaccines unit in Gujarat, India to domestic clinical biotechnology company, Bharat Biotech.
• In 2019, Wuhan Institute of Virology announced positive results of a novel rabies vaccine in pre-clinical test. The novel vaccine is a live attenuated vaccine; VEEV-RABV-G.
• In June 18, 2020 Bavarian Nordic A/S and Valneva SE announced a partnership for marketing and distribution of rabies and tick-borne vaccines in selected European countries and Canada.